Local factories supply a small share of the medicines used in Mainland Tanzania, and the Ministry of Health wants that share to rise sharply by 2030. Reported estimates of the current share run from under 10 to about 20 per cent, and the 2030 target has been given as 50, 60, 65, 70 and 80 per cent in different reports this year. None of these numbers comes with a published definition of what is being counted. A factory can cut exposure to import delays and price swings, but it does not put medicine on a shelf by itself. Ingredients, payment, quality approval and distribution have to work as well. This analysis weighs the evidence and sets out what it means for people working in pharmacy.
- How much medicine is made locally?
- The targets do not yet agree either
- Making a medicine locally is not the same as making its ingredients
- Why imports still win on price
- What the government has set in motion
- Choose the medicines before counting the factories
- What local production can secure, and what it cannot
- What it means for pharmacy practice
- Measures that would show progress
The figures concern Mainland Tanzania. Zanzibar has its own health and medicines regulatory arrangements, and none of the sources reviewed says how these targets apply there.
How much medicine is made locally?
The baseline is not settled, and the spread is itself a finding.
| Figure | Source | What it says |
|---|---|---|
| 6.9% and 2.8% | TMDA figures for 2020, quoted in a World Bank Group diagnostic | Share of medicinal products, and of human medicinal products, made in the country. The measure is not defined. |
| About 80% imported | The same diagnostic (2023) | Share of medicines and medical devices used locally that are imported |
| About 90% imported | Deputy Permanent Secretary Emmanuel Tayari, in The Citizen | Share of medicines imported |
| About 10% | Tayari, in The Citizen (date not shown) | Share of national demand met by domestic manufacturers |
| 10% to 20% | Ministry of Health 2026/27 budget figures, as reported by HabariLeo on 9 October 2026 | Share of national need |
| About 20% | Ministry of Health report of 13 October 2026, as reported by The Chanzo | Share of demand |
The World Bank Group diagnostic, prepared by consultants from Ernst & Young from desk research and about 28 interviews, counted 41 medical product manufacturing facilities in 2023. Seventeen made pharmaceuticals and 24 made medical devices. It reported 11 more pharmaceutical plants under construction, five companies with Good Manufacturing Practice (GMP) certification and one firm accounting for about 70 per cent of locally made pharmaceuticals. Daily News reports put the import bill at roughly US$1 billion, or TZS 2.6 trillion, a year.
These figures come from officials and consultants, use different definitions of “demand” and have not been independently audited. Definitions matter. A 2023 study in the Journal of Pharmaceutical Policy and Practice by Baldeh and colleagues notes that Kenya, Tanzania and Uganda count any company registered and domiciled locally as a local manufacturer, whatever its ownership or level of manufacturing. A company that only packs imported products can therefore sit in the same statistics as one that formulates from raw materials. The Minister for Health made the same point at the TAPHATA meeting, according to Mfamasia’s coverage: progress should be judged by what is made in Tanzania, not by what is only repackaged or distributed.
The targets do not yet agree either
At the Tanzania Pharmaceutical Technicians Association (TAPHATA) annual meeting in Arusha, Minister Mohamed Mchengerwa said the government wants 80 per cent of domestic medicine demand met by local manufacturing by 2030, as Mfamasia reported on 27 October 2026 and Daily News also reported. Daily News reported on 23 July 2026 that President Samia Suluhu Hassan set the same 80 per cent aim for 2030, while quoting the minister as expecting more than 65 per cent of medicines to be made domestically by 2030.
Other reports give different numbers:
- A Daily News report says the government announced earlier this year a plan to raise local production from about 10 per cent to between 60 and 65 per cent by 2030.
- The Citizen’s headline on 1 July 2026 gave the President’s target as 60 per cent by 2030.
- In June, Mwananchi quoted the minister hoping to reach at least 50 per cent within three years.
- The Chanzo lists a January statement of 65 per cent by 2030, a Medical Stores Department (MSD) statement of 80 per cent in May, a figure of more than 60 per cent given to Parliament on 13 October and a reported 70 per cent at the TAPHATA conference. It also reports the January baseline as about 10 per cent, so the starting point has been restated too.
The Chanzo piece is commentary, and its author argues that the measure is undefined. It could be the share of products by number, by volume or by value, and it may or may not include medical devices and reagents. The author also asks whether locally packed products made from imported ingredients are counted as domestic production. Those are the author’s arguments, not confirmed policy, but the questions are fair and only the Ministry can answer them.
For regional context, the East African Community’s 2017 to 2027 manufacturing plan, as summarised in the World Bank Group diagnostic, aims to cut dependence on imports from outside the region from more than 70 per cent to below 50 per cent. The diagnostic notes that Tanzania was far from that target.
Making a medicine locally is not the same as making its ingredients
Most Tanzanian manufacturers formulate finished products, such as tablets, capsules and liquids, from imported active pharmaceutical ingredients (APIs, the substances that make a medicine work), excipients (the inactive substances that give a product its form and stability) and packaging. The World Bank Group diagnostic reports that APIs and excipients are sourced entirely abroad and that local firms have concentrated on over-the-counter medicines, generic antimalarials, antiretrovirals and antibiotics.
Local finishing still builds skills and can shorten lead times. It does not protect a plant that cannot obtain ingredients, packaging or spare parts. Medicine security therefore depends on more than the share of finished products made at home. It also depends on where ingredients come from, how many suppliers a plant can use, how much stock is held and how quickly production can adapt to a disruption. Making every input locally is unrealistic for most products, so a mix of local production of priority medicines, diversified sourcing and strategic stock is the more practical aim. That is analysis, not an official position.
Why imports still win on price
MSD buys for the public sector and is the largest single customer for local manufacturers. The World Bank Group diagnostic reports that MSD pays a 15 per cent price preference to local products, yet most imports remain cheaper even with that margin.
The same report points to a payment gap. When MSD buys from international suppliers it opens a letter of credit and sometimes pays in advance. Local manufacturers must deliver on credit, so they borrow to fund working capital, and that borrowing raises their prices. Reliable payment may therefore lower local prices more than a wider price preference would. Other cost pressures named in the report include:
- Raw materials. Local manufacturers are entitled to import tax exemption on raw materials, but excipients and packaging are usually taxed in practice, because the exemption was being misused for other purposes.
- Utilities. Unreliable grid power and water push manufacturers towards generators and water treatment, which cost more.
- Finance. Banks are reluctant to lend for new pharmaceutical plants without a production record, and local firms must offer collateral up front.
- Skills and equipment. Training produces general-practice pharmacists, not industrial pharmacy specialists. Some firms bring in foreign technicians to maintain new machines.
There are two sides to the preference debate. Manufacturers argue that a wider margin or advance payment would let them compete. Public buyers and patients face tight budgets, and the diagnostic itself suggests reviewing the 15 per cent preference with safeguards so medicines stay affordable. At TAPHATA, investors also asked for advance payments through MSD and VAT relief on locally made medical devices.
What the government has set in motion
The Ministry of Health has built a set of measures around investment, procurement and regulation:
- Industrial zones. The foundation stone of the Mloganzila Pharmaceutical Industrial Park in Dar es Salaam was laid on 8 May 2026, according to The Citizen. Mr Tayari told The Citizen that Mloganzila and a second site at Bagamoyo total 700 acres, with investment of US$5 billion to US$10 billion expected over a decade. Area figures differ between reports. The Chanzo cites the Ministry of Health as saying 386 of 400 acres at Mloganzila have been allocated to 11 investors.
- Investor pipeline. The Chanzo reports that 83 investors have shown interest, 57 have been evaluated and six are close to implementation.
- Incentives. The Citizen reports that firms in the zones can receive a 10-year corporate tax holiday and VAT and import duty exemptions on production inputs.
- Shared laboratory. The government has committed US$10 million to a shared quality-control and bioequivalence laboratory, according to The Guardian on 22 June 2026.
- Quality and registration. In December 2025 the Minister launched a strategy that ties incentives to attaining World Health Organization (WHO) GMP standards, with a mandatory roadmap to WHO certification and registration of local products cut to 60 days, The Guardian reported. A ministerial task force was formed to monitor time-bound targets, and a separate Pharmaceutical Investment Acceleration Taskforce works with investors.
- Procurement. In presenting the 2026/27 health budget in May, the Minister said MSD would give priority to locally made medicines that meet Tanzania Medicines and Medical Devices Authority (TMDA) standards before importing, Daily News reported. A planned circular that would require importers to submit local production plans as a licensing condition was reported by Mwananchi. That is a stated plan, not an enacted rule.
- Named projects. Daily News reports that China’s Africare Biopharma and Hualan Ankang Biologics have committed to plants at Kurasini in Dar es Salaam and Bagamoyo, with construction expected from September 2026 and completion within two years. The planned products include medicines for HIV prevention, diabetes and hepatitis.
Universal health insurance began on 26 January 2026, according to Daily News, which should raise the volume of medicines bought. More demand does not by itself guarantee that local firms win the orders.
Allocation is not production
These are plans, applications and commitments. The sources reviewed describe preparation, not output from new plants. Each factory still has to secure finance, build, install and qualify equipment, recruit staff, pass inspection and obtain authorisation for each product. Progress is best reported in those terms: what is built, what is inspected, which products are authorised, how much is produced and whether it is bought.
The Tanzania Pharmaceutical Industries (TPI) plant in Arusha is an early test. In December 2025, The Guardian reported that MSD and the Treasury Registrar had entered a joint venture with TPI to revive and modernise the factory for antiretroviral (ARV) production. The Minister directed in January that production begin by June 2026, and Daily News reported that trial production was scheduled for May. The Chanzo says the public has not been told whether the money was released, whether production began or whether the plant obtained GMP approval. This analysis found no verified confirmation that commercial production began. Rehabilitation, commissioning and commercial production are different stages, and until TPI or TMDA confirms the plant’s authorised products and output, it should not be described as a dependable supplier.
Choose the medicines before counting the factories
Baldeh and colleagues compared local production with the national essential medicines lists of the three countries, using 2018 data. They found four Tanzanian manufacturers with 97 locally produced products, of which 39 were essential medicines. That covered 5 per cent of the national list (24 of 510 items), against 21 per cent in Kenya and 10 per cent in Uganda. Tanzania had no locally made essential medicine in 17 of 28 therapeutic classes, and many local essential products duplicated one another. The data are old, but the lesson holds: investment should follow the essential medicines list, disease burden, procurement demand and technical feasibility, not add more brands of products already widely sold.
Complexity matters too. Conventional tablets, capsules and oral liquids are the realistic starting point. The minister has urged pharmacy professionals to prepare for vaccines, insulin and specialised cancer medicines, Daily News reported. Those need more demanding facilities, expertise and quality controls, and their timelines should reflect that.
What local production can secure, and what it cannot
It can improve reach. Mujinja and colleagues analysed World Health Organization and Health Action International price surveys from 2006 and 2009 in four regions. Medicines made in Tanzania were as likely to be found in rural outlets as in urban ones, while imports from outside East Africa, mainly from India, were significantly less likely to reach rural areas. The data are old and cover tracer medicines, but they suggest local suppliers may reach places that import-focused supply chains do not.
It cannot fix the last stretch. Many shortages arise between the central warehouse and the patient, through forecasting gaps, late funding and weak facility stock records, as Mfamasia’s analysis of why medicines run short shows. A tablet made in Dar es Salaam can still be missing at a dispensary if the order, payment or delivery fails. Public availability figures are lowest at dispensaries, so local production helps most if it comes with better ordering and distribution.
It cannot guarantee quality by origin. “Local” is not a quality claim. GMP certification, TMDA registration and batch-level checks are the relevant standards. The December 2025 strategy itself treats the lack of WHO certification as a barrier to selling beyond the local market, according to The Guardian. The diagnostic counted only five GMP-certified companies in 2023, so inspection and laboratory workloads will grow as plants multiply, and TMDA needs the capacity to match.
What it means for pharmacy practice
Hospital and procurement pharmacists. Track supplier delivery times, quality complaints, price and stock-outs for local and imported products, so comparisons use real data and not impressions.
Dispensing and counselling. A locally made generic needs the same checks as an imported one: TMDA registration, batch details, storage conditions and expiry. When a patient’s usual product changes manufacturer, the tablet’s appearance may change, so teams should explain it, without implying that country of origin decides quality. See Mfamasia’s guides on generic medicines and on spotting counterfeit, substandard and falsified products.
Reporting. New manufacturers mean new products entering the market. Pharmacists who report suspected adverse reactions and quality complaints through TMDA channels give regulators early signals. Recall procedures matter more as the number of suppliers grows, as set out in what pharmacies should do when a medicine is recalled.
Purchasing. Private pharmacies and Accredited Drug Dispensing Outlets (ADDOs) can ask wholesalers where a product is made and how reliably it is supplied. Good stock records, as discussed in Mfamasia’s inventory guide, show which lines run short and for how long, which is useful evidence for suppliers and regulators.
Careers. Plants need production, quality assurance, quality control, formulation, validation and regulatory staff. The skills gap in industrial pharmacy is one point on which the World Bank Group report and the minister agree, and the roles are set out in Mfamasia’s TAPHATA coverage. Graduates should note that these jobs depend on plants actually opening.
Measures that would show progress
- Facilities completed, inspected and producing commercially.
- GMP inspection findings and how they are closed.
- More essential medicines produced where supply gaps exist.
- Actual output and deliveries, not installed capacity.
- Availability at hospitals, health centres, dispensaries, pharmacies and rural outlets.
- Prices that remain affordable, and payment terms for local suppliers.
- Reliable access to APIs, excipients and packaging.
- A published definition of the self-sufficiency percentage, with a baseline and annual milestones.
- The importer licensing circular, if issued, with its legal basis and effective date.
The test is whether quality-assured medicines are consistently available at an affordable price, not how many factories are announced.
